CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study

Next Previous
Trial Profile

CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Coversin (Primary)
  • Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Acronyms CONSERVE
  • Sponsors Akari Therapeutics

    • Most Recent Events

    • 24 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top